Pro-Dex, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended June 30, 2023. Although the request metadata references “2022 Q4,” this filing is the company’s annual report for FY2023; it also restates prior-period financial information. Amounts below are U.S. dollars.
Business context
Pro-Dex designs and manufactures powered surgical instruments, principally for orthopedic, thoracic, and craniomaxillofacial markets, and also provides repairs, engineering services, and rotary air motors. It operates as one segment. The company moved assembly and repair operations to its Tustin facility during FY2023.
Financial performance
| Metric | FY2023 | FY2022, restated |
|---|---|---|
| Net sales | $46.1 million | $42.0 million |
| Gross profit / margin | $12.7 million / 28% | $13.1 million / 31% |
| Operating income / margin | $5.8 million / 13% | $5.1 million / 12% |
| Net income | $7.1 million | $4.6 million |
| Diluted earnings per share | $1.95 | $1.21 |
| Operating cash flow | $5.5 million | $(0.8) million |
- Sales grew 10%, led by repairs, up $6.0 million, and non-recurring engineering and prototype services, up $1.7 million. Medical-device product sales fell $3.3 million, or 10%.
- Gross margin declined to 28% from 31%, reflecting higher material and labor costs and greater manufacturing under-absorption. Cost of sales rose 15%.
- Operating expenses declined 13% to $7.0 million, primarily on lower general and administrative costs. Operating income increased 12%.
- Net income included $3.9 million of unrealized investment gains, principally related to the Monogram warrant. This noncash item materially contributed to reported earnings growth; it should not be confused with operating performance.
- FY2023 operating cash flow benefited from a $5.4 million reduction in receivables, partly offset by a $3.5 million inventory increase. Investing cash outflow was $0.9 million; financing cash outflow was $2.5 million.
Liquidity, debt, and capital
- At June 30, 2023, cash and cash equivalents were $2.9 million, working capital was $21.3 million, and total assets were $51.8 million.
- Total notes payable were approximately $12.7 million: $3.8 million current and $8.9 million long-term. The company also reported $2.1 million of lease liabilities.
- The amended revolving facility is $7.0 million, with $2.5 million drawn and $4.5 million available at year-end. A separate $3.0 million supplemental line was undrawn. Management said available resources and expected operating cash flows should cover needs for at least 12 months.
- The company repurchased 86,422 shares for $1.5 million during FY2023. It has not paid cash dividends.
Changes, outlook, and significant matters
- Restatement: The company corrected its prior valuation of a warrant to buy Monogram Orthopaedics shares. The warrant had been assigned little or no value in earlier periods; the corrected fair value was $6.2 million at June 30, 2023, versus $2.3 million at June 30, 2022. The restatement revised investment values, unrealized gains, taxes, and net income for FY2021, FY2022, and interim periods through March 2023. It did not change previously reported revenue, operating income, cash, or cash flows.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective. The company identified a material weakness in accounting for and disclosing Level 3 instruments, including the Monogram warrant, and said remediation was underway but not yet established as effective.
- Backlog: Firm purchase-order backlog was $41.6 million at June 30, 2023, up from $16.5 million a year earlier. $31.4 million was expected to ship in FY2024 and $10.2 million in FY2025. Backlog is not a guarantee of revenue; customer order timing can vary.
- Management outlook: Management expects a similar volume of enhanced repairs for its largest customer in FY2024 and expects higher thoracic revenue following a new distributor agreement, but gives no assurance. It expects product-development investment to increase. The ENT shaver project listed an expected Q4 2023 market launch and estimated annual revenue of $1.0 million; the ventilator project was suspended.
- Customer and supplier concentration: The three largest customers represented 92% of FY2023 sales; the largest alone represented 67%. The top two represented 83% of sales and 92% of receivables. Supplier delays, longer lead times, higher prices, and surcharges continued to affect operations.
- Subsequent event: On October 6, 2023, after year-end, Pro-Dex exercised the Monogram warrant for $1.25 million in cash and received 1,828,551 Monogram shares. The reported October 6 closing price was $2.67 per share.
Key investor verification points
- Review the restated statements and quarterly reconciliations, especially the warrant valuation assumptions and resulting noncash gains and taxes.
- Track whether the material weakness remediation is implemented, tested, and reported as effective.
- Assess the sustainability and margins of enhanced repairs, and whether new product and distributor opportunities convert into recurring revenue.
- Monitor customer concentration, order cancellations or shipment delays, backlog conversion, inventory levels, and supplier constraints.
- Verify debt covenant compliance, revolving-facility availability and maturity/refinancing needs, and the liquidity and valuation risks of thinly traded investments.